Alpine Immune Sciences (ALPN) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN – Research Report) yesterday and set a price target of $19.00. The company’s shares closed last Tuesday at $10.19. More »

Motus Gi Holdings (MOTS) Receives a Buy from Oppenheimer

In a report released yesterday, Steven Lichtman from Oppenheimer maintained a Buy rating on Motus Gi Holdings (MOTS – Research Report), with a price target of $2.50. The company’s shares closed last More »